Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial-Reference-Cited by-同舟云学术

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Published:2016-09 Issue:9 Volume:17 Page:1306-1316
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Saad Fred,Carles Joan,Gillessen Silke,Heidenreich Axel,Heinrich Daniel,Gratt Jeremy,Lévy Jérémy,Miller Kurt,Nilsson Sten,Petrenciuc Oana,Tucci Marcello,Wirth Manfred,Federhofer Judith,O'Sullivan Joe M

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Horwich;Ann Oncol,2013

2. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer;DePuy;Support Care Cancer,2007

3. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer;Halabi;J Clin Oncol,2008

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

5. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

Cited by 253 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japanese clinical practice guidelines for prostate cancer 2023;International Journal of Urology;2024-07-30

2. Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra;Cancers;2024-07-29

3. Targeted Radiopharmaceutical Therapy for Bone Metastases;Seminars in Nuclear Medicine;2024-07

4. The Bone Pathway: 223Ra-Dichloride;Radiopharmaceuticals;2024

5. External beam radiotherapy in treatment of high-volume metastatic hormone-sensitive prostate cancer: clinical case;Cancer Urology;2023-11-14